首页> 美国卫生研究院文献>British Medical Journal >Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
【2h】

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study

机译:注意缺陷/多动障碍(ADHD)的儿童和年轻人中哌醋甲酯的心血管安全性:全国性自控病例系列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events.>Design Self controlled case series analysis.>Setting Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea.>Participants 1224 patients aged ≤17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate.>Main outcome measures A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication.>Results Increased risk of arrhythmia was observed in all exposed time periods—that is, periods of treatment with methylphenidate—(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure.>Conclusion The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
机译:>目的:确定在患有注意力缺陷/多动障碍(ADHD)的儿童和青少年中使用哌醋甲酯治疗是否与心血管事件相关。>设计自控病例系列分析。 strong> Settings 于2008年1月1日至2011年12月31日在韩国建立的全国健康保险数据库。>参与者 1224岁≤17岁的患者经历了心血管事件并至少有1位患者>主要结局指标:有记录的以下任何心血管不良事件的诊断(主要或次要原因):心律失常(ICD-10(国际疾病分类,第10版)代码) I44,I45,I47,I48,I49),高血压(代码I10-I15),心肌梗塞(代码I21),缺血性中风(代码I63)或心力衰竭(代码I50)。通过条件Poisson回归计算发病率比率,并针对随时间变化的合并症和喜剧进行调整。>结果在所有暴露时间段(即哌醋甲酯治疗期间),心律失常的风险均增加了(发生率比率为1.61,95%的置信区间为1.48至1.74),而先天性心脏病患儿的风险最高。在所有暴露时间段(1.33,0.90至1.98)均未观察到明显的心肌梗塞风险,尽管在开始使用哌醋甲酯治疗后的8至56天的早期风险期内风险更高。未观察到高血压,缺血性中风或心力衰竭的显着风险增加。>结论。在开始使用哌醋甲酯治疗儿童多动症后的早期,心肌梗塞和心律不齐的相对风险增加。人。尽管绝对风险可能较低,但应谨慎考虑哌醋甲酯的风险与收益平衡,尤其是在轻度ADHD患儿中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号